Peroxiredoxins in colorectal neoplasms

Histology and Histopathology

Volumn 25, Issue 10, 2010, Pages 1297-1303

  Wu, X Y ^a   Fu, Z X ^a   Wang, X H ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Antioxidant; Colorectal neoplasms; Peroxiredoxin; Reactive oxygen species

Indexed keywords

ISOPROTEIN; PEROXIREDOXIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMISTRY; CHI SQUARE DISTRIBUTION; CHINA; COLORECTAL TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CHI-SQUARE DISTRIBUTION; CHINA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEROXIREDOXINS; PROGNOSIS; PROTEIN ISOFORMS; UP-REGULATION;

EID: 79952021380     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Chae H.Z., Chung S.J. and Rhee S.G. (1994). Thioredoxin-dependent peroxide reductase from yeast. J. Biol. Chem. 269, 27670-27678.
2. Chae H.Z., Kim I.H., Kim K. and Rhee S.G. (1993). Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae. J. Biol. Chem. 268, 16815-16821.
3. Chang J.W., Jeon H.B., Lee J.H., Yoo J.S., Chun J.S., Kim J.H. and Yoo Y.J. (2001). Augmented expression of peroxiredoxin I in lung cancer. Biochem. Biophys. Res. Commun. 289, 507-512.
4. Chen M.F., Keng P.C., Shau H., Wu C.T., Hu Y.C., Liao S.K. and Chen W.C. (2006). Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int. J. Radiat. Oncol. Biol. Phys. 64, 581-591.
5. Ekbom A., Helmick C., Zack M. and Adami H.O. (1990). Increased risk of large bowel cancer in Crohn's disease with colonic involvement. Lancet 336, 357-359.
6. Fridovich J. and Freeman B. (1986). Antioxidant defenses in the lung. Annu. Rev. Physiol. 48, 693-702.
7. Hess A., Wijayanti N., Neuschäfer-Rube A.P., Katz N., Kietzmann T. and Immenschuh S. (2003). Phorbol ester-dependent activation of peroxiredoxin I gene expression via a protein kinase C, Ras, p38 mitogen-activated protein kinase signaling pathway. J. Biol. Chem. 278, 45419-45434.
8. Iwao-Koizumi K., Matoba R., Ueno N., Kim S.J., Ando A., Miyoshi Y., Maeda E., Noguchi S. and Kato K. (2005). Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 23, 422-431.
9. Jang J.S., Cho H.Y., Lee Y.J., Ha W.S. and Kim H.W. (2004). The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol. Res. 14, 491-499.
10. Jin D.Y., Chae H.Z., Rhee S.G. and Jeang K.T. (1997). Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J. Biol. Chem. 272, 30952-30961.
11. Kang S.W., Baines I.C. and Rhee S.G. (1998). Characterization of a mammalian peroxiredoxin that contains one conserved cysteine. J. Biol. Chem. 273, 6303-6311.
12. Karihtala P., Mäntyniemi A., Kang S.W., Kinnula V.L. and Soini Y. (2003). Peroxiredoxins in breast carcinoma. Clin. Cancer Res. 9, 3418-3424.
13. Kim H., Lee T.H., Park E.S., Suh J.M., Park S.J., Chung H.K., Kwon O.Y., Kim Y.K., Ro H.K. and Shong M. (2000). Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J. Biol. Chem. 275, 18266-18270.
14. Kinnula V.L., Lehtonen S., Sormunen R., Kaarteenaho-Wiik R., Kang S.W., Rhee S.G. and Soini Y. (2002). Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J. Pathol. 196, 316-323.
15. Knoops B., Clippe A., Bogard C., Arsalane K., Wattiez R., Hermans C., Duconseille E., Falmagne P. and Bernard A. (1999). Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family. J. Biol. Chem. 274, 30451-30458.
16. Lee S.C., Chae H.Z., Lee J.E., Kwon B.D., Lee J.B., Won Y.H., Ahn K.Y. and Kim Y.P. (2000). Peroxiredoxin is ubiquitously expressed in rat skin: isotype-specific expression in the epidermis and hair follicle. J. Invest. Dermatol. 115, 1108-1114.
17. Lin J.F., Xu J., Tian H.Y., Gao X., Chen Q.X., Gu Q., Xu G.J., Song J.D. and Zhao F.K. (2007). Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int. J. Cancer 121, 2596-2605.
18. Liu X., Zeng B., Ma J. and Wan C. (2009). Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell. Cancer Invest. 27, 345-352.
19. Loguerico C. and Federico A. (2003). Oxidative stress in vrial and alcoholic hepatitis. Free Radic. Biol. Med. 34, 1-10.
20. Memon A.A., Chang J.W., Oh B.R. and Yoo Y.J. (2005). Identification of differentially expressed proteins during human urinary bladder cancer progression. Cancer Detect. Prev. 29, 249-255.
21. Nair J., Gansauge F., Beger H., Dolara P., Winde G. and Bartsch H. (2006). Increased etheno-DNA adducts in affected tissues of patients suffering from Crohn's disease, ulcerative colitis, and chronic pancreatitis. Antioxid. Redox Signal. 8, 1003-1010.
22. Park H.J., Kim B.G., Lee S.J., Heo S.H., Kim J.Y., Kwon T.H., Lee E.B., Ryoo H.M. and Cho J.Y. (2008). Proteomic profiling of endothelial cells in human lung cancer. J. Proteome Res. 7, 1138-1150.
23. Park S.H., Chung Y.M., Lee Y.S., Kim H.J., Kim J.S., Chae H.Z. and Yoo Y.D. (2000). Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin. Cancer Res. 6, 4915-4920.
24. Parkin D.M. (2006). The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044.
25. Pelicano H., Carney D. and Huang P. (2004). ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 7, 97-110.
26. Qi Y., Chiu J.F., Wang L., Kwong D.L. and He Q.Y. (2005). Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 5, 2960-2971.
27. Rabilloud T., Heller H., Gasnier F., Luche S., Rey C., Aebersold R., Benahmed M., Louisot P. and Lunardi J. (2002). Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J. Biol. Chem. 277, 19396-19401.
28. Rhee S.G., Chae H.Z. and Kim K. (2005). Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med. 38, 1543-1552.
29. Roessner A., Kuester D., Malfertheiner P. and Schneider-Stock R. (2008). Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol. Res. Pract. 204, 511-524.
30. Sánchez-Font M.F., Sebastià J., Sanfeliu C., Cristòfol R., Marfany G. and Gonzàlez-Duarte R. (2003). Peroxiredoxin2 (PRDX2), an antioxidant enzyme, is under-expressed in Down syndrome fetal brains. Cell Mol. Life Sci. 60, 1513-1523.
31. Seo M.S., Kang S.W., Kim K., Baines I.C., Lee T.H. and Rhee S.G. (2000). Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J. Biol. Chem. 275, 20346-20354.
32. Shen C. and Nathan C. (2002). Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells. Mol. Med. 8, 95-102.
33. Shen J., Person M.D., Zhu J., Abbruzzese J.L. and Li D. (2004). Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 64, 9018-9026.
34. Sies H. (1993). Strategies of antioxidant defense. Eur. J. Biochem. 215, 213-219.
35. Yamashita H., Avraham S., Jiang S., London R., Van Veldhoven P.P., Subramani S., Rogers R.A. and Avraham H. (1999). Characterization of human and murine PMP20 peroxisomal proteins that exhibit antioxidant activity in vitro. J. Biol. Chem. 274, 29897-29904.
36. Yanagawa T., Ishikawa T., Ishii T., Tabuchi K., Iwasa S., Bannai S., Omura K., Suzuki H. and Yoshida H. (1999). Peroxiredoxin I expression in human thyroid tumors. Cancer Lett. 145, 127-132.
37. Yanagawa T., Iwasa S., Ishii T., Tabuchi K., Yusa H., Onizawa K., Omura K., Harada H., Suzuki H. and Yoshida H. (2000). Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 156, 27-35.
38. Yim M.B., Chae H.Z., Rhee S.G., Chock P.B. and Stadtman E.R. (1994). On the protective mechanism of the thiol-specific antioxidant enzyme against the oxidative damage of biomacromolecules. J. Biol. Chem. 269, 1621-1626.
39. Yo Y.D., Chung Y.M., Park J.K., Ahn C.M., Kim S.K. and Kim H.J. (2002). Synergistic effect of peroxiredoxin II antisense on cisplatininduced cell death. Exp. Mol. Med. 34, 273-277.
40. Zhang P., Liu B., Kang S.W., Seo M.S., Rhee S.G. and Obeid L.M. (1997). Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J. Biol. Chem. 272, 30615-30618.